An interventional study of Virtual T-maze task in Refractory Epilepsy, sponsored by University Hospital, Ghent. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.
Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Drug Resistant Epilepsy with a site in Belgium — 5 open to participants now, 6 under way, 1 of them phase 3. Drug Resistant Epilepsy · Belgium.
Among the 17 studies in Drug Resistant Epilepsy with a site in Belgium, this one is the 8th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 8 with no phase, and was the 7th registered.
258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.
Browse Drug Resistant Epilepsy studies →5 of the 17 studies in Drug Resistant Epilepsy with a site in Belgium are open now. Recruiting first, the newest first:
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Sites in Belgium
Ages 3+
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Sites in Belgium
Ages 18–60 · Healthy volunteers
Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Sites in Belgium
Ages 18–79
Biohaven Therapeutics Ltd. · Sites in Belgium, United States, Argentina and 24 more countries
Ages 18–75
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 3
First in 2012; this study’s year is marked. 2 started in 2021.
This study's planned enrollment of 40 is above the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.
Median enrollment 40 across the 15 interventional studies, 509 across the 2 observational. Of the 10 that completed or were terminated, 3 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 17 have an industry lead sponsor. The 10 most frequent:
University Hospital, Ghent is the lead sponsor of 689 studies on the registry; 157 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
University Hospital, Ghent has 3 studies filed under Drug Resistant Epilepsy — fewer than ten, so there is no comparison to draw.
2 of the studies in Drug Resistant Epilepsy with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies in Drug Resistant Epilepsy with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The exact function of the anterior cingulate cortex (ACC) is one of the largest riddles in cognitive neuroscience and a major challenge in mental health research. ACC dysfunction contributes to a broad spectrum of neurological and psychiatric disorders, such as depression, ADHD, Parkinson's disease, OCD and many others, but nobody knows what it actually does. Recently a new theory has been developed about ACC function; the HRL-ACC (Hierarchical Reinforcement Learning Theory of ACC). This theory proposes that the ACC selects and motivates high-level tasks based on the principles of hierarchical reinforcement learning. The ACC associates values with tasks, selects the correct tasks and applies control over other neural networks (such as the dorsolateral prefrontal cortex and basal ganglia), which execute the tasks. The values of these tasks are attributed based on "reward prediction error signals", which are sent from the midbrain dopamine system to the ACC. These signals can be recorded using scalp-EEG as an "event-related brain potential" (ERP), which is called the "reward positivity". Until this day, the exact origin of the reward positivity is not yet known. Studies have delivered strong indirect evidence that the reward positivity is generated in the ACC. However, there is an important lack of direct evidence to support this hypothesis. The goal of this study is to provide direct evidence that the reward positivity is generated in the ACC by letting a group of patients with refractory epilepsy perform the virtual T-maze task (which is known to elicit reward positivity) and simultaneously recording intracranial video-EEG.
This is a monocentric prospective interventional clinical trial that will include patients with refractory epilepsy and for whom a hospitalization at the Centre for Neurophysiological Monitoring (CNM) at the University Hospital Ghent is planned for invasive video-EEG recording. This hospitalization is part of a pre-surgical work-up to determine if the patient is eligible for resective surgery. It is important to note that the decision to plan the patient for invasive video-EEG monitoring is made by neurologists and neurosurgeons specialized in refractory epilepsy and is in no way connected to this study.
Every patient that will be admitted to the CNM for invasive video-EEG monitoring has a consultation with Prof. Dr. Alfred Meurs about one month before hospitalization. During this consultation, Prof. Meurs will ask if the patient is willing to participate in this study. If the patient agrees and has given informed consent, the first session of the study will take place directly after the consultation. However, if the patient is not available at that time, a new appointment will be made for the first session. The first session has to take place before admission to the CNM.
The study consists of two experimental sessions. The first session takes place after giving informed consent and before admission to the hospital for invasive video-EEG monitoring. Therefore, this session is completely study-specific and may require and extra visit to the hospital if the patient is not available right after the consultation with Prof. Meurs.
During this session, the patient will perform the virtual T-maze task for 20 minutes while scalp-EEG will be recorded simultaneously. During this task, patients will see a T-maze on a computer screen and have to choose at every junction whether they go left or right. Depending on the direction they choose, they get rewarded or not. This feedback will elicit the reward positivity.
The rationale for this first session is that it is important to know whether or not the patient produces a normal reward positivity measured by scalp EEG, before the intracranial electrodes are placed.
The second session takes place during the admission at the CNM, after the intracranial electrodes are placed. The invasive video-EEG monitoring is part of a pre-surgical work-up and is planned independently from the study. During this session, the patient will once again have to perform the virtual T-maze task while scalp-EEG and intracranial-EEG will simultaneously be recorded.
After the two sessions, the data will be analysed using ERP analysis and the amplitude of the reward positivity will be calculated for every electrode. It is expected that the amplitude of the reward positivity ERP-component will be largest for patients with electrodes in the frontal lobe, located closely to the ACC. This will deliver direct evidence that the reward positivity is in fact generated in the ACC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each participant will undergo two sessions, consisting of performing the virtual T-maze task, scalp-EEG recording and/or intracranial video-EEG recording.
Behavioral: Virtual T-maze task
Patients will have to perform the virtual T-maze task, which is known to elicit reward positivity. During this task, the patients will see a virtual T-maze on a computer screen and have to choose at every junction whether they go right or left. Depending on the direction they choose, they either get positive or negative feedback (reward or no reward). This feedback is chosen completely at random, on a 50% reward/50% no reward basis.
Distribution of reward positivity amplitude
Calculation of amplitude of reward positivity ERP-component recorded by intracranial electrodes and scalp-distribution of amplitude across all subjects
Time frame: Date of inclusion to date of second session (about one month)
Location in brain most likely to represent source of reward positivity
Electrode with highest reward positivity amplitude and corresponding location in brain, analysis across all subjects
Time frame: Date of inclusion to date of second session (about one month)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2021 (actual). Primary completion is estimated for Sep 2024, 42 months after the start.
Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 42 months is above that.
Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.